APGE — Apogee Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $2.30bn
- $1.48bn
- 26
- 34
- 89
- 47
Annual cashflow statement for Apogee Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K |
| Standards: | USG | USG |
| Status: | Final | Final |
| Net Income/Starting Line | -39.8 | -84 |
| Non-Cash Items | 13.5 | 3.12 |
| Other Non-Cash Items | ||
| Changes in Working Capital | 9.81 | 6.11 |
| Change in Prepaid Expenses | ||
| Change in Other Assets | ||
| Change in Accounts Payable | ||
| Change in Accrued Expenses | ||
| Cash from Operating Activities | -16.4 | -74.8 |
| Capital Expenditures | — | -0.167 |
| Purchase of Fixed Assets | ||
| Other Investing Cash Flow Items | — | -274 |
| Sale/Maturity of Investment | ||
| Purchase of Investments | ||
| Cash from Investing Activities | — | -274 |
| Net Issuance / Retirement of Stock | ||
| Cash from Financing Activities | 168 | 315 |
| Beginning Cash Balance | ||
| Ending Cash Balance | ||
| Net Change in Cash | 152 | -33.3 |